Randomized phase II study of two different doses of RAD-001 (everolimus) as neo-adjuvant therapy in patients with localized prostate cancer

Trial Profile

Randomized phase II study of two different doses of RAD-001 (everolimus) as neo-adjuvant therapy in patients with localized prostate cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jun 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top